Bielpamtek Acquires Additional 727,272 Shares of Gwangdong HealthBio, Expanding Stake to 13.96%

Bielpamtek (065170) announced on July 13 that it has decided to acquire 727,272 shares of Gwangdong HealthBio for 104,727 million won in cash. The transaction involves Magna ABC Fund, a venture investment consortium based in Gangnam, Seoul, with Magna Investment as its managing director and Park Ki-il as CEO. No special relationship exists between Bielpamtek and the fund. Gwangdong HealthBio, a health functional food manufacturer with CEO Jeong Hwa-young, has a capitalization of 63,4393 million won and a total issued share count of 12,687,865 shares. The acquisition, valued at 104,727 million won, represents 10.55% of Bielpamtek's equity (as of the latest financial statements). The transaction is expected to close on July 13, 2026, coinciding with the board resolution date. Post-acquisition, Bielpamtek will own 1,779,580 shares or 13.96% of Gwangdong HealthBio, aiming to strengthen collaboration through new product development. Gwangdong HealthBio's 2025 financials show assets of 62,260 million won, liabilities of 43,917 million won, equity of 18,289 million won, revenue of 66,980 million won, and a net loss of 6,400 million won. Bielpamtek's 2025 financials: assets 18,200 million won, liabilities 10,300 million won, equity 7,900 million won, revenue 6,500 million won, operating loss 2,800 million won, and net loss 16,800 million won. Bielpamtek, listed on KOSDAQ since November 19, 2002, operates in the food and tobacco wholesale sector. As of July 13, 2026, its share price closed at 3,065 won, down 580 won (-15.91%) from the previous day.